FREMONT, Calif., April 28, 2014 /PRNewswire/ -- ValGenesis, Inc., the Global market leader in Validation Lifecycle Management Solutions (VLMS), announced today it has released multi organization functionality along with multilingual support for global life science companies. The latest version of ValGenesis VLMS is the most enhanced, integrated and proven validation lifecycle management platforms adopted by global life science companies. Already featuring the highest level of configurability, ValGenesis VLMS now provides newer capabilities that enable the rapid, parallel deployment of Validation Lifecycle Management system globally for different groups or business units or sites in enterprise environments in parallel whilst supporting multiple language deployment for regional users. ValGenesis's multisite function helps to connect geographically distributed sites – providing users the ability to efficiently collaborate and manage all types of validation processes in a closed loop, with Risk Assessment and Change Management requirements. ValGenesis's Multisite function enables you to think and act globally for all your validation planning, with the flexibility to manage the projects locally.
Latest version of ValGenesis VLMS also includes enhanced Dashboard with 360 degree visibility for the validation process across multiple sites. In addition, it provides user-friendly configuration tools and best practice templates built from years of industry experience, thus enabling standardization, consistency and compliance in the corporate validation process across any site or organization. Availability of multi-site function helps organizations to enforce the approved validation plan, policies and procedures across multiple business units or sites or geography which are typically buried in approved documents.
"ValGenesis as an organization has gained significant momentum in 2013 with the addition of number of new growth-oriented customers, including several Fortune 500 global Life Sciences organizations as customers. Additionally, many of the existing customers have expanded use of the ValGenesis solutions by doubling the number of users using the system, rolling out new sites and validation processes, there by confirming that ValGenesis provides the most comprehensive, cost-effective and easily configurable Validation Lifecycle management solutions in the market" said Narayan Raj, VP of Sales and Business Development.
"The response that we have received for the latest version of ValGenesis software system has been tremendous, as it is the first solution to truly manage the Validation Lifecycle process as paperless across multiple sites of global Life science companies," said Dr. Siva Samy, Chief Product Strategist, ValGenesis Inc. Further added, "Our continued growth clearly shows that we are a recognized leader not only because of our exponential growth, but also because of our out-of-the-box solution is tried and proven in accordance with industry best validation practices."
ValGenesis, Inc. is the provider of an innovative software platform designed to provide the foundation for compliance-based validation activities in Life Sciences companies. ValGenesis, Inc. provides the first Enterprise application to manage the corporate validation lifecycle process. Through an industry peer review committee, the Parenteral Drug Association (PDA) recognized the ValGenesis solution with its very prestigious New Innovative Technology award. The ValGenesis suite is designed to be fully compliant with U.S. FDA 21 CFR Part 11 and Annex 11 requirements. For more information, visit the ValGenesis website at http://www.valgenesis.com.
Mike Beaudro, Marketing Manager
ValGenesis, Inc. | 42840 Christy St. | Fremont, CA 94538
Ph: 510 445 0505 | Email
Read more news from ValGenesis, Inc.
SOURCE ValGenesis, Inc.